实用肿瘤杂志2017，Vol.32Issue(2)：168-172,5.
不同制剂紫杉醇联合表柔比星治疗晚期乳腺癌的临床观察
Efficacy of different formulations of paclitaxel combined with pirarubicin in treatment of advanced breast cancer
涂俊 1杨娟 1刘景丽 1瞿广桥1
作者信息
- 1. 武汉科技大学附属孝感医院肿瘤科,湖北孝感432000
- 折叠
摘要
Abstract
Objective To investigate the clinical efficacy and toxicity of paclitaxel or albumin-bound paclitaxel combined with pirarubicin in treatment of advanced breast cancer.Methods Sixty-two patients with advanced breast cancer were assigned to study group and control group with 31 cases in each group.Patients in study group received albumin-bound paclitaxel(260 mg/m2) combined with pirarubicin(75 mg/m2),and those in control group received paclitaxel(175 mg/ m2) combined with pirarubicin(75 mg/m2).The clinical efficacy and adverse reactions of the two groups were observed and compared after 2 cycles of chemotherapy.Results The total effective rate of study group was 93.5％ (29/31),which was significantly higher than that of control group (71.0％,22/31;x2 =5.42,P =0.020).No statistically significant difference was observed in the occurrence of adverse reactions between two groups (P ＞ 0.05).Conclusion Albumin-bound paclitaxel has a better clinical effect than paclitaxel when combined with pirarubicin in treating advanced breast cancer,and the adverse reactions are tolerable in both protocols.关键词
乳腺肿瘤/药物疗法/表柔比星/投药和剂量/表柔比星/治疗应用/药物疗法,联合/紫杉酚/投药和剂量/紫杉酚/类似物和衍生物/血清白蛋白/双盲法/治疗结果Key words
breast neoplasms/drug therapy/epirubicin/administration & dosage/epirubicin/therapeutic use/drug therapy/combination/paclitaxel/administration & dosage/paclitaxel/analogs & derivatives/serum albumin/double-blind method/treatment outcome分类
医药卫生引用本文复制引用
涂俊,杨娟,刘景丽,瞿广桥..不同制剂紫杉醇联合表柔比星治疗晚期乳腺癌的临床观察[J].实用肿瘤杂志,2017,32(2):168-172,5.
